Vokanamet: new combination oral hypoglycaemic

Janssen-Cilag has launched a twice-daily fixed dose combination tablet containing canagliflozin and metformin for the treatment of type II diabetes.

Vokanamet (canagliflozin/metformin) is available as 50mg/850mg and 50mg/1g tablets.
Vokanamet (canagliflozin/metformin) is available as 50mg/850mg and 50mg/1g tablets.

Vokanamet (canagliflozin/metformin) is indicated in adults aged 18 years and older with type II diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in patients:

  • not adequately controlled on their maximally tolerated doses of metformin alone
  • receiving maximally tolerated doses of metformin along with other glucose-lowering medicinal products including insulin, when these do not provide adequate glycaemic control 
  • already being treated with the combination of canagliflozin and metformin as separate tablets.

As an inhibitor of SGLT2 glucose transporters in the kidney, canagliflozin has a complementary glucose-lowering action to that of metformin.

Vokanamet is taken as a single tablet twice daily with food, and is available in two presentations containing 50mg canagliflozin plus either 850mg or 1g metformin. The initial strength of tablet should be selected on the basis of the patient’s current metformin dose.

When adding Vokanamet to a regimen containing insulin or a sulfonylurea, prescribers should consider lowering the dose of insulin and/or sulfonylurea to reduce the risk of hypoglycaemia.

View Vokanamet drug record

Further information: Janssen-Cilag

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

SGLT2 inhibitors: risk of diabetic ketoacidosis

SGLT2 inhibitors: risk of diabetic ketoacidosis

Patients receiving SGLT2 inhibitors (canagliflozin,...

Metformin use in renal impairment extended

Metformin use in renal impairment extended

Metformin can now be used in patients with moderate...

Xultophy: first insulin/incretin mimetic combination launched

Xultophy: first insulin/incretin mimetic combination launched

Xultophy is a prefilled pen containing a fixed-ratio...

Canagliflozin approved by NICE for diabetes

Canagliflozin approved by NICE for diabetes

NICE has approved canagliflozin (Invokana) for use...

Invokana: new SGLT2 inhibitor for type II diabetes

Invokana: new SGLT2 inhibitor for type II diabetes

Janssen-Cilag has launched Invokana (canagliflozin)...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more